Dear Sir/Madam, With reference to the email dated 21st November, 2025, please find attached revised outcome of the Board meeting held on 14th November, 2025. You are requested to ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prism Medico and Pharmacy Ltd has re-submitted the outcome of its November 14, 2025 board meeting. The re-upload was needed because the scanned PDF of the Statement of Assets and Liabilities and Cash Flow Statement was inadvertently missed in the original filing, though the data was already present in the XBRL file submitted to BSE and MSEI. The board approved unaudited standalone financial results for Q2 and H1 FY26 (ended September 30, 2025), which received an unqualified limited review report from auditors Garg Mendiratta & Associates. For Q2 FY26 standalone, the company posted a net loss of ₹8.48 lakhs on revenue of ₹50.23 lakhs, compared to a profit of ₹0.94 lakhs on revenue of ₹28.78 lakhs in Q2 FY25. For H1 FY26, net profit was ₹65.73 lakhs on revenue of ₹158.87 lakhs, versus ₹57.25 lakhs profit on ₹209.10 lakhs revenue in H1 FY25. Operating cash flow turned positive at ₹39.07 lakhs in H1 FY26 against a negative ₹1.65 lakhs for the full FY25.
Mixed signals for shareholders: Q2 standalone swung to a loss even as revenue grew sharply quarter-on-quarter, while the half-year picture shows revenue declining about 24% year-on-year despite higher profits, likely due to cost compression. The auditor gave a clean review report, but the filing lapse (missing PDF pages) reflects weak compliance hygiene, which investors should note even though it has now been rectified.